# Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

> **NCT01795313** · PHASE1 · TERMINATED · sponsor: **James Felker** · enrollment: 23 (actual)

## Conditions studied

- Ependymoma

## Interventions

- **BIOLOGICAL:** HLA-A2 restricted synthetic tumor antigen
- **DRUG:** Imiquimod
- **OTHER:** enzyme-linked immunosorbent assay
- **OTHER:** flow cytometry
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01795313
- **Lead sponsor:** James Felker
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08
- **Primary completion:** 2025-12-03
- **Final completion:** 2025-12-03
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Closed supratentorial arm prematurely secondary to lack of enrollment
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01795313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01795313, "Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01795313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*